Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …

Background The evasion from apoptosis is a common strategy adopted by most tumors, and
inhibitors of apoptosis proteins (IAPs) are among the most studied molecular and …

Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies.
Activation of BCR signaling promotes the survival and proliferation of malignant B cells …

Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-
Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of …

In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …

Bruton's tyrosine kinase (BTK) regulates multiple important signaling pathways and plays a
key role in the proliferation, survival, and differentiation of B-lineage cells and myeloid cells …

Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is
largely considered to be one of the primary mechanisms driving disease progression in B …

Abstract FDG‐PET/CT is the current state‐of‐the‐art imaging in lymphoma and plays a
central role in treatment decisions. At diagnosis, accurate staging is crucial for appropriate …

Long term outcomes and mutations in patients with mantle cell lymphoma (MCL) who
discontinued ibrutinib have not been described. Using deep targeted next generation …